See below, Specialised Therapeutics’ Company Update for December 2016. To view this publication, move your mouse over the image below and click on the Fullscreen button in the top right corner to expand the window.
+65 3158 9940
1300 798 820
+64 9801 0299
See below, Specialised Therapeutics’ Company Update for December 2016. To view this publication, move your mouse over the image below and click on the Fullscreen button in the top right corner to expand the window.
August, 2016: In Australia, the cost of treating some cancers is undoubtedly becoming more expensive. Physicians frequently express concern about the cost of prescribing innovative branded medicines because of the significant taxpayer contribution required to fund the PBS. Further, they concede that they are mindful of the public purse when it comes to this sort of decision making.
HERALD SUN (MELBOURNE) By Grant McArthur 5 November 2016 Linda Defies Odds: Brave cancer survivor is determined to live life to the full FEW people would laugh about their superannuation running out while they still have a lot of living left to do. But for Linda Wilson, the prospect of outliving her nest egg
Specialised Therapeutics Australia (STA) has a particular interest in pancreatic cancer and is committed to supporting efforts to advance understanding and improve clinical outcomes in this disease. Testimony to this commitment, we recently sponsored well-known television personality and sports broadcaster Tiffany Cherry to participate in the GI Cancer Institute’s ‘Gutsy Challenge’ – a seven day
Melbourne, Australia: Two Australian patients have undergone surgery with the aid of a new drug which assists neurosurgeons to visualise and remove high grade gliomas – brain tumours which typically have a poor prognosis. Neurosurgeons at Brisbane’s Wesley Hospital and the Royal Melbourne Hospital have pioneered the use of Gliolan® (5-aminolevulinic acid), describing it
Charleston, South Carolina and Singapore, October 12, 2016: Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the “Company”) and Specialised Therapeutics Asia (“STA”) today announced the signing of an exclusive license agreement for the Company’s lead investigational anti-cancer compound, Zoptrex™ (zoptarelin doxorubicin), for the territories of Australia and New Zealand (the “Territory”). Zoptrex™, a novel synthetic
Earlier this week, pharmaceutical companies across the country copped a hefty financial blow, as the Federal Government’s PBS cost saving agenda took flight. Under this plan, expected to save the Federal Government around $3.7 billion over the next five years, all branded medicines that have been listed on the PBS for five years or more
Two and a half years ago, Melbourne based high flyer Shelli Whitehurst was diagnosed with Stage 4 breast cancer. The devastating diagnosis inspired her to found a business that’s now helping other cancer patients around the world. Shelli Whitehurst was at the pinnacle of her career, enjoying the success of the marketing business she founded
“I think the biggest revolutions in pancreas cancer treatment are yet to come.” Dr Lorraine Chantrill has been a medical oncologist for 10 years, with a particular focus on pancreatic cancer “because it is so terrible and there is so much room for improvement”. She notes that average survival rates for pancreas cancer have improved
“Oral mucositis is quite debilitating, because pain in your mouth, or ulceration in your mouth, makes it hard to eat and to swallow.” “Pretty much every cancer agent can cause some degree of mouth or gut damage. But it all depends on which drugs and what doses you are using. The range of incidence is